Affymetrix Names Kevin King President of Life Sciences Business
News Jan 02, 2007
Affymetrix Inc. has announced that it has appointed Kevin M. King to president of life sciences business and executive vice president, reporting to Stephen P.A. Fodor, Ph.D., chairman and CEO.
King previously served as president and CEO of Thomson Healthcare, the $500 million healthcare and pharmaceutical information services division of Thomson Corporation.
"We are very pleased to add Kevin King to the Affymetrix executive management team," said Fodor.
"He is an experienced leader and his proven track record of operational success in the life sciences industry provides Affymetrix with a solid foundation for continued commercial growth."
According to Affymetrix, King will be responsible for managing its life sciences business, which serves hundreds of academic, government, pharmaceutical and industrial customers around the world. He brings more than 25 years of industry experience to Affymetrix.
At Thomson Healthcare, King was responsible for developing and implementing the growth strategy. King has also held senior executive positions at General Electric Healthcare, including vice president and general manager, Global Clinical Systems.
In addition, King brings more than 14 years of experience at Hewlett-Packard, where his many accomplishments included the creation of a web-enabled systems strategy.
"Affymetrix microarray technology has quickly become the gold standard in life science research," said King.
"I look forward to being a part of such a quality organization that has tremendous opportunities to accelerate scientific research and improve patient care."
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE